Фармакокинетические свойства и дозиметрические характеристики радиофармпрепаратов на основе бифосфоновой и пентафосфоновой кислот с генераторными радионуклидами 99mTc и 188Re
Диссертация
Для этих целей наиболее перспективными соединениями являются производные фосфороорганических кислот. Фосфонаты ингибируют процессы минерализации и резорбции кости. Отмеченные свойства фосфонатов открывают путь для клинического изучения указанных комплексов при нарушении минерального обмена, таких, например, как эктопическая кальцификация и повышенная деструкция костей. Кроме того, сродство… Читать ещё >
Список литературы
- Закутинский, Д.И. Справочник по токсикологии радиоактивных изотопов / Д. И. Закутинский, Ю. Д. Парфенов, Л. И. Селиванова. М.: Медгиз, 1962. — 116 с.
- Касаткин, Ю.Н. Двадцатилетний опыт радиойодтерапии больных токсическим зобом / Ю. Н. Касаткин, И. И. Пурижанский // Московский медицинский журнал. 1999. — № 1. — С. 17−19.
- Комаров, И.Г. Метастазы злокачественных опухолей без выявленного первичного очага / И. Г. Комаров, Д. В. Комов. М.:Триада-Х, 2002. -136 с.
- Корн, Г. Справочник по математике для научных работников и инженеров / Г. Корн, Т. Корн. М.: Наука, 1984. — 832 с.
- Крживицкий, П.И. Клинико-лучевая диагностика метастатического поражения скелета / П. И. Крживицкий // Практическая онкология. -2011.-Т. 12. -№ 3. С. 103−111.
- Лишманов, Ю.Б. Радионуклидная диагностика для практических врачей / Ю. Б. Лишманов, В. И. Чернов. Томск: 8ТТ, 2004. — 394 с.
- Ноздрачев, А.Д. Анатомия крысы / А. Д. Ноздрачев, Е. Л. Поляков. -СПб.: издательство «Лань», 2001. 464 с.
- Петриев, В.М. Влияние концентрации реагентов и кислотности реак188ционной среды на комплексообразующую способность Яе с гидро-ксиэтилидендифосфоновой кислотой / В. М. Петриев // Радиохимия. -2008. Т. 50. — № 2. — С. 173−177.
- Петриев, В.М. Влияние концентрации Эп2"1″ на комплексообразующую способность 99мТс с калий-натриевой солью оксиэтилидендифосфоно-вой кислоты / В. М. Петриев, В. Г. Скворцов, Т. П. Рыжикова // Радиохимия. 2007. — Т.49. — № 3. — С. 258−261.
- Степаненко, В.Ф. Радиобиологическая значимость электронов малых энергий при внутреннем гамма-электронном облучении (радиационные аспекты): дис.. канд. биол. наук: 03.01.01 / Степаненко Валерий Федорович. НИИМР, г. Обнинск, 1978.
- Степаненко, В.Ф. Расчет распределения поглощенных доз внутреннего облучения / В. Ф. Степаненко, Т. А. Норец // Медицинская радиология. 1977. — Т. 22. — № 10. — С. 67−73.
- Степаненко, В.Ф. Расчет распределения поглощенной энергии при внутреннем облучении моноэнергетическими электронами / В. Ф. Степаненко, Т. А. Норец // Радиобиология. 1978. — Т. 28. — № 3. — С. 412 417.
- Степаненко, В.Ф. Изоэнергетические функции протяженных источников моноэнергетических электронов с энергией от 0,5 кэВ до 1 МэВ / В. Ф. Степаненко, Т. А. Норец. М., 2002. — 18 с. — Деп. в ВИНИТИ 19.03.1980, № 1065−80.
- Ali, I. Visualization of hepatic metastases of medullary thyroid carcinoma on Tc-99m MDP bone scintigraphy / I. Ali, W. Johns, S.M. Gupta // Clin. Nucl. Med. 2006. — V. 31. — No. 10. — P. 611−613.
- Asikoglu, M. The rabbit biodistribution of a therapeutic dose of zoledronic acid labeled with Tc-99m / M. Asikoglu, F.G. Durak // Appl. Radiat. Isot. -2009.-V. 67.-No. 9.-P. 1616−1621.
- Ashayeri, E. Strontium 89 in the treatment of pain due to diffuse osseous metastases: a university hospital experience / E. Ashayeri, A. Omogbehin, R. Sridgar, R.A. Shankar // J. Natl. Med. Assoc. 2002. — V. 94. — No. 8. -P. 706−711.
- Bensimhon, L. Influence of temperature on the radiochemical purity of 99mTc-colloidal rhenium sulfide for use in sentinel node localization / L. Bensimhon, T. Metaye, J. Guilhot, R. Perdrisot // Nucl. Med. Commun. -2008.-V. 29.-No. 11.-P. 1015−1020.
- Berk, F. Hepatic and splenic uptake of Tc-99m HDP in multiple myeloma: additional findings on Tc-99m MIBI and Tc-99m sulfur colloid images / F.
- Berk, H. Demir, A. Hacihanefioglu, A. Arslan, O. Erdincler, S. Isgoren, C. Aktolun//Ann. Nucl. Med.-2002.-V. 16.-No. 2.-P. 137−141.
- Berquist, T.H. MRI of the Musculoskeletal System / T.H. Berquist. 5 ed.- Lippincott Williams and Wilkins, 2006. 1008 p.
- Blake, G.M. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases / G.M. Blake, M.A. Zivanovic, R.M. Blaquiere, D.R. Fine, A.J. McEwan, D.M. Ackery // J. Nucl. Med. 1988. — V. 29. — No. 4.- P. 549−557.
- Brenner, W. Skeletal uptake and soft — tissue retention of 186Re HEDP and 153Sm — EDTMP in patients with metastatic bone disease / W. Brenner,
- W.U. Kampen, A.M. Kampen, E. Henze 11 J. Nucl. Med. 2001. — V. 42. -P. 230−236.
- Bruland, O.S. Targeted radiotherapy of osteosarcoma using 153Sm-EDTMP. A new promising approach / O.S. Bruland, A. Skretting, O.P. Solheim, M. Aas // Acta. Oncol. 1996. — V. 35. — No. 3. — P. 381−384.
- Brundage, M.D. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone: Provincial Genitourinary Cancer Disease Site Group / M.D. Brundage, J.M. Crook, H. Lukka // Cancer Prev. Control. 1998. -V.2.-P. 79−87.
- Carr, E.A. Jr. Uptake of technetium-99m methylene diphosphonate by fractured and osteoporotic bone after a pulse dose of vitamin D3 / E.A. Carr, Jr, M. Carroll, M. Monies, M. Zielezny // J. Nucl. Med. 1985. — V. 26. — No. 4.-P. 385−389.
- Carrasquillo, J.A. Alendronate does not interfere with 99mTc-methylene diphosphonate bone scanning / J.A. Carrasquillo, M. Whatley, V. Dyer, W.D. Figg, W. Dahut // J. Nucl. Med. 2001. — V. 42. — P. 1359−1363.
- Casara, D. Rhabdomyosarcoma concentrating Tc-99m MDP / D. Casara, A. Bonazza // J. Nucl. Med. 1983. — V. 24. — No. 11. — P. 1082−1083.
- Chakraborty, S. Preparation and biological evaluation of 153Sm-DOTMP as a potential agent for bone pain palliation / S. Chakraborty, T. Das, S.
- Banerjee, P.R. Chaudhari, H.D. Sarma, M. Venkatesh, M.R. Pillai // Nucl. Med. Commun. -2004. V. 25.-No. 12.-P. 1169−1176.
- Cheung, A. Evaluation of radioactive phosphorus in the palliation of metastatic bone lesions from carcinoma of the breast and prostate / A. Che-ung, A. A. Driedger//Radiology.- 1980.-V. 134.-No. l.-P. 209−212.
- Choong, P.F. The molecular basis of skeletal metastases / P.F. Choong // Clin. Orthop. 2003. — V. 41. — P. 19−31.
- Clezardin, P. Anti-tumour activity of zoledronic acid / P. Clezardin // Cancer Treat. Rev. 2005. — V. 31(Suppl 31−38). — P. 134s-6230s.
- Coleman, R.E. Bisphosphonates in breast cancer / R.E. Coleman // Ann. Oncol. 2005. — V. 16. — P. 687−695.
- Coleman, R.E. Skeletal complications of malignancy / R.E. Coleman // Cancer 1997,-V. 80(8Suppl). — P. 1588−1594.
- Cook, G.J. Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography / G.J. Cook, I. Fogelman // Q. J. Nucl. Med. 2001. — V. 45. — No. 1. — P. 47−52.
- Cook, G.J. The role of positron emission tomography in the management of bone metastases / G.J. Cook, I. Fogelman // Cancer. 2000. — V. 88. — P. 2927−2933.
- Coxon, F.P. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells / F.P. Coxon, K. Thompson, A.J. Roelofs, F.H. Ebetino, M.J. Rogers // Bone. 2008. — V. 42. — P. 848−860.
- Cronhjort, M. Sympathotropic drugs and the distribution of 99mTc-hydro-xymethylene diphosphonate. Experimental studies in the mouse / M. Cronhjort, C. Jonsson, H. Jacobsson // Acta. Radiol. 1999. — V. 40. — No. 3.-P. 309−313.
- Daffner, R.H. MRI in the detection of malignant infiltration of bone marrow / R.H. Daffner, A.R. Lupetin, N. Dash, Z.L. Deeb, R.J. Sefczek, R.L. Schapiro // AJR Am. J. Roentgenol. 1986. — V. 146. — P. 353−358.
- Dalinka, M.K. Complications of radiation therapy / M.K. Dalinka, V.P. Mazzeo // Crit. Rev. Diagn. Imaging. 1985. — V. 23. — P. 235−267.
- Das, T. (170)Tm-EDTMP: a potential cost-effective alternative to (89)SrCl (2) for bone pain palliation / T. Das, S. Chakraborty, H.D. Sarma, P. Tandon, S. Banerjee, M. Venkatesh, M.R. Pillai // Nucl. Med. Biol. -2009. V. 36. — No. 5. — P. 561−568.
- Das, T. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation / T. Das, S. Chakraborty, P.R. Unni, S. Banerjee, G. Samuel, H.D. Sarma, M. Venkatesh, M.R. Pillai // Appl. Radiat. Isot. -2002.-V. 57.-No. 2.-P. 177−184.
- Dolezal, J. Efficacy and toxicity of 153samarium-EDTMP in painful breast cancer bone metastases / J. Dolezal // Onkologie 2009. — V. 32. — P. 3539.
- Dolezal, J. Systemic radionuclide therapy with Samarium-153-EDTMP for painful bone metastases / J. Dolezal // Nucl. Med. Rev. Cent. East. Eur. -2000. V. 3. -No. 2. — P. 161−163.
- Dolezal, J. Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer / J. Dolezal, J. Vizda, K. Odrazka // Urol. Int. 2007. — V. 78. — No. l.-P. 50−57.
- Dunstan, C.R. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease / C.R. Dunstan, D. Felsenberg, M.J. Seibel // Nat. Clin. Pract. Oncol. 2007. — V. 4. — P. 42−55.
- Ell, P.J. Skeletal imaging in metastatic disease / P.J. Ell // Curr. Opin. Radiol. 1991. — V. 3. — No. 6.-P. 791−796.
- Etchebehere, E.C. Treatment of bone pain secondary to metastases using samarium-153-EDTMP / E.C. Etchebehere, C.A. Pereira Neto, M.C. Lima, O. Santos Ade, C.D. Ramos, C.M. Silva, E.E. Camargo // Sao Paulo Med. J. 2004. — V. 122. — No. 5. — P. 208−212.
- Evans, A.J. Magnetic resonance imaging versus radionuclide scintigraphy for screening in bone metastases / A.J. Evans, J.F. Robertson // Clin. Radiol. 2000. — V. 55. — No. 8. — P. 653−654.
- Fogelman, I. A comparison of skeletal uptakes of three diphosphonates by whole-body retention: concise communication / I. Fogelman, D.W. Pearson, R.G. Bessent, A J. Tofe, M.D. Francis // J. Nucl. Med. 1981. — V. 22.-No. 10.-P. 880−883.
- Fuster, D. Usefulness of strontium-89 for bone palliation in metastatic breast cancer patients / D. Fuster, D. Herranz, S. Vidal-Sicart, M. Munoz, C. Conill, J.J. Mateos, F. Martin, F. Pons //Nucl. Med. Commun. 2000. -V.21.-No. 7.-P. 623−626.
- Garty, I. Unusual extraosseous tumoral accumulation of 99mTc-MDP / I. Garty, J. Risescu, G. Rosen, I. Bar-llan // Eur. J. Nucl. Med. 1985. — V. 10.-No. 7−8.-P. 362−365.
- Gunawardana, D.H. Results of strontium-89 therapy in patients with prostate cancer resistant to chemotherapy / D.H. Gunawardana, M. Lichtenstein, N. Better, M. Rosenthal // Clin. Nucl. Med. 2004. — V. 29. — No. 2. -P. 81−85.
- Hamdy, N.A. The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates / N.A. Hamdy, S.E. Papapoulos // Semin. Nucl. Med. 2001. — V. 31. — P. 62−68.
- Hashimoto, K. Adsorbtion of 188Re complexes with aminomethylene-phosphonate on hydroxyapatite / K. Hashimoto, H. Matsuoka, M. Izumo // J. Nucl. Radiochem. Sciences. 2001. — V. 2. — No. 1−2. — P. 5−9.
- Henriksen, G. Targeting of osseous sites with a emitting 223Ra: comparison with P emitter 89Sr in mice / G. Henriksen, D.R. Fisher, J.C. Roeske, O.S. Bruland, R.H. Larsen // J. Nucl. Med. 2003. — V. 74. — P. 252−259.
- Holmes, R.A. 153Sm.EDTMP: a potential therapy for bone cancer pain / R. A. Holmes // Semin. Nucl. Med. 1992. — V. 22. — No. 1. — P. 41−45.
- Hommeyer, S.H. Skeletal nonvisualization in a bone scan secondary to intravenous etidronate therapy / S.H. Hommeyer, D.M. Varney, J.F. Eary // J. Nucl. Med. 1992. — V. 33. — P. 748−750.
- Hsieh, B.T. Comparison of various rhenium 188-labelled diphosphonates for the treatment of bone metastases / B.T. Hsieh, J.F. Hsieh, S.C. Tsai, W.Y. Lin, S.J. Wang, G. Ting // Nucl. Med. Biol. 1999. — V. 26. — P. 973−976.
- Hughes, D.E. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo / D.E. Hughes, K.R. Wright, H.L. Uy, A. Sasaki, T. Yoneda, G.D. Roodman, G.R. Mundy, B.F. Boyce // J. Bone Miner. Res. -1995.-V. 10.-No. 10.-P. 1478−1487.
- Idris, A.I. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro / A.I. Idris, J. Rojas, I.R. Greig, R.J. Van’t Hof, S.H. Ralston // Calcif. Tissue Int. 2008. — V. 82. — No. 3. — P. 191 201.
- Ikehira, H. Multiple extra-bone accumulations of technetium-99m-HMDP / H. Ikehira, Y. Furuichi, M. Kinjo, Y. Yamamoto, T. Aoki // J. Nucl. Med. Technol. 1999. — V. 27. — No. 1. — P. 41−42.
- Isacson, J. Scintigraphic findings in the rheumatoid knee joint / J. Isacson, J. Rydberg, L.A. Brostrom // Scand. J. Rheumatol. 1988. — V. 17. — No. 5.-P. 333−339.
- Kanishi, D. 99mTc-MDP accumulation mechanisms in bone / D. Kanishi // Oral Surg. Oral Med. Oral Pathol. 1993. — V. 75. — No. 2. — P. 239−246.
- Kawamura, E. Splenic accumulation of Tc-99m HMDP in a patient with severe alcoholic cirrhosis of the liver / E. Kawamura, J. Kawabe, T. Haya-shi, A. Oe, J. Kotani, K. Torii, D. Habu, S. Shiomi // Clin. Nucl. Med. -2005. V. 30. — No. 5. — P. 351−352.
- Kenney, J. Traser studies with radioactive phosphorus in malignant neoplastic disease / J. Kenney, L. Marinelli, H. Woodarad // Radiology. -1941.-V. 37.-P. 683−687.
- Ketring, A.R. 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals / A.R. Ketring // Int. J. Rad. Appl. Instrum. B. 1987. -V. 14.-No. 3.-P. 223−232.
- Koizumi, M. Transient splenic accumulation of Tc-99m HMDP caused by megaloblastic anemia / M. Koizumi, T. Suzuki, S. Takahashi, E. Ogata // Clin. Nucl. Med. 2000. — V. 25. — No. 12. — P. 1024−1027.
- Kothari, K. Preparation, stability studies and pharmacological behavior of, 86Re. Re-HEDP / K. Kothari, M.R. Pillai, P.R. Unni, H.H. Shimpi, O.P. Noronha, A.M. Samuel // Appl. Radiat. Isot. 1999. — V. 51. — P. 51−58.
- Krasnow, A.Z. Diagnostic bone scanning in oncology / A.Z. Krasnow, R.S. Hellman, M.E. Timins, B.D. Collier, T. Anderson, A.T. Isitman // Semin. Nucl. Med. 1997. — V. 27. -P. 107−141.
- Kumar, D. Evaluation of biodistribution by local versus systemic administration of 99mTc-labeled pamidronate / D. Kumar, V. Kumar, D.G. Little, R.B. Howman-Giles, E. Wong, S.O. Ali // J. Orthop. Sci. 2006. — V. 11. -No. 5.-P. 512−520.
- Kumar, V. Is (99m)Tc-labelled pamidronate a better agent than (99m)Tc-medronate for bone imaging? / V. Kumar, D. Kumar, R.B. Howman-Giles, D.G. Little // Nucl. Med. Commun. 2007. — V. 28. — No. 2. — P. 101−107.
- Lambert, B. Clinical applications of 188Re-labelled radiopharmaceuticals for radionuclide therapy / B. Lambert, J.M. de Klerk // Nucl. Med. Commun. 2006. — V. 27.-No. 3.-P. 223−229.
- Laznicek, M. 99Tcm-DTPMP as a skeletal scintigraphy agent: distribution in rats in comparison with 99Tcm-MDP / M. Laznicek, A. Laznickova, F. Budsky//Nucl. Med. Commun. 1996. — V. 17.-No. 12.-P. 1016−1020.
- Li, S. Rhenium-188 HEDP to treat painful bone metastases / S. Li, J. Liu, H. Zhang, M. Tian, J. Wang, X. Zheng // Clin. Nucl. Med. 2001. — V. 26. -P. 919−922.
- Liepe, K. Comparison of rhenium-188, rhenium- 186-HEDP and strontium-89 in palliation of painful bone metastases / K. Liepe, W.G. Franke, J. Kropp, R. Koch, R. Runge, R. Hliscs // Nuklearmedizin. 2000. — V. 39. -P. 146−151.
- Liepe, K. Rhenium-188-HEDP in the palliative treatment of bone metastases / K. Liepe, R. Hliscs, J. Kropp, T. Gruning, R. Runge, R. Koch, F.F.Jr. Knapp, W.G. Franke // Cancer Biother. Radiopharm. 2000. — V. 15. -No. 3.-P. 261−265.
- Liepe, K. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases / K. Liepe, R. Hliscs, J. Kropp, R. Runge, F.F. Knapp, W.G. Franke // J. Nucl. Med. 2003. — V. 44. — No. 6. -P. 953−960.
- Liepe, K. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases / K. Liepe, J. Kotzerke // Nucl. Med. Commun. 2007. — V. 28. — No. 8. — P. 623−630.
- Liepe, K. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain / K. Liepe, R. Runge, J. Kotzerke // J. Cancer Res. Clin. Oncol.-2005.-V. 131.-No. 1.-P. 60−66.
- Lin, W. Effect of reaction conditions on preparations of rhenium-188 hydroxy ethyl idene diphosphonate complexes / W. Lin, J.F. Hsieh, C.P. Lin, B.T. Hsieh, G. Ting, S.J. Wang, F.F. Knapp // Nucl. Med. Biol. 1999. -V. 26.-P. 455−459.
- Lungu, V. Radiolabeled phosphonates for bone metastases therapy / V. Lungu, D. Niculae, P. Bouziotis, I. Pirmettis, C. Podina // J. Radioanal. Nucl. Chem. 2007. — V. 273. — No. 3. — P. 663−667.
- MacDonald J. Idiopathic Hepatic uptake of 99mTc methylene diphosphonate: a case report / J. MacDonald // J. Nucl. Med. Technol. -2001.-V. 29.-P. 26−30.
- Martin, W.H. Detection of malignancies with SPECT versus PET, with 2-fluorine-18.fluoro-2-deoxy-D-glucose / W.H. Martin, D. Delbeke, J.A. Patton, M.P. Sandler//Radiology. 1996.-V. 198.-No. l.-P. 225−231.
- Maxfield, J.R. The use of radioactive phosphorus and testosterone in metastatic bone lesions from breast and prostate / J.R. Maxfield, J.G. Maxfield, W.S. Maxfield // South Med. J. 1958. — V. 52. — No. 3. — P. 320−327.
- McAfee, J.G. Experimental drug-induced changes in renal function and biodistribution of 99mTc-MDP / J.G. McAfee, A. Singh, M. Roskopf, C.
- Ritter, B. Lyons, J.E. Schoonmaker, F.D. Thomas, D. Jones // Invest. Radiol. 1983. — V. 18.-No. 5.-P. 470178.
- McAfee, J.G. Changes in renal uptake of Tc-99m methylene diphosphonate (MDP) in stone-forming rats / J.G. McAfee, F.D. Thomas, M. Roskopf, K. Ritter, B. Lyons, O.M. Lilien, J.E. Schoonmaker // Invest. Radiol. 1984. -V. 19.-No. 6.-P. 543−548.
- McCarthy, I.D. The role of skeletal blood flow in determining the uptake of 99mTc-methylene diphosphonate / I.D. McCarthy, S.P. Hughes // Calcif. Tissue Int. 1983.-V. 35.-P. 508−511.
- McKinstry, P. Relationship of 99mTc-MDP uptake to regional osseous circulation in skeletally immature and mature dogs / P. McKinstry, J.E. Schnitzer, T.R. Light, J.A. Ogden, P. Hoffer // Skeletal Radiol. 1982. -V. 8.-No. 2.-P. 115−121.
- Miller, A.D. Radiophosphorous (P32) treatment in carcinoma of the breast and prostate: report of 39 cases / A.D. Miller // J. Am. Osteopath. Assoc. -1974. V. 74. — No. 3. — P. 217−222.
- Nicolay, O.F. Autoradiographic localization of technetium-99 methylene diphosphonate in growth sites of young mice / O.F. Nicolay, J.D. Heeley, M.K. Jeffcoat, A.G. Jones // Int. J. Rad. Appl. Instrum. B. 1988. — V. 15. -No. 2.-P. 157−163.
- Nozaki, T. Usefulness of single photon emission computed tomography imaging in the detection of lumbar vertebral metastases from prostate cancer / T. Nozaki, K. Yasuda, T. Akashi, H. Fuse // Int. J. Urol. 2008. — V.15.-No. 6.-P. 516−519.• 188
- Oh, S.J. Preparation and biological evaluation of Re-ethylenediamine
- N, N, N', N'-tetrakis (methylenephosphonic acid) as a potential agent for bone pain palliation / S.J. Oh, K.S. Won, D.H. Moon, J.H. Cheon, H.J. Ha, J.M. Jeong, H.K. Lee //Nucl. Med. Commun. 2002. — V. 23. — P. 75−81.
- Oka, M. A comparison of 99mTc-MDP and 99mTc-pertechnetate by computerized quantitative joint scintigraphy / M. Oka, T.T. Mottonen, A. Re-konen//Scand. J. Rheumatol. 1983.-V. 12.-No. l.-P. 4618.
- Ozarda, A.T. Detection of a brain metastasis from osteosarcoma with 99mTc-methylene diphosphonate bone scanning / A.T. Ozarda, J.R. Legaspi, T.P. Haynie //Eur. J. Nucl. Med. 1983.-V. 8.-No. 12.-P. 552−554.
- Ozdogan, O. Does cisplatin chemotherapy decrease the MDP uptake of normal bone? An experimental study / O. Ozdogan, T. Ertay, G. Arslan,
- A.R. Sisman, G. Capa Kaya, O. Yilmaz, C. Coker, A. Gure, H. Durak // Ann. Nucl. Med. 2008. — V. 22. — No. 5. — P. 357−362.
- Paes, F.M. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain / F.M. Paes, A.N. Serafini // Semin. Nucl. Med.-2010.-V. 40.-No. 2.-P. 89−104.
- Pandit-Taskar, N. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases / N. Pandit-Taskar, M. Batraki, C.R. Divgi // J. Nucl. Med. 2004. — V. 45. — No. 8. — P. 1358−1365.
- Papapoulos, S.E. Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis / S.E. Papapoulos // IJCP. 2003. -V. 57.-P. 417−422.
- Parker, C. Overall survival benefit of radium-223 chloride (Alpharadin) in the treatment of patients with symptomatic bone metastasesin castration-resistant prostate cancer (CRPC): a phase III randomised trial
- ALSYMPCA) / C. Parker, D. Heinrich, J.M. O’Sullivan, et al. // Presented at the European Multidisciplinary Cancer Congress, Stockholm, Sweden. -September 23−27, 2011.
- Ridley, A.J. The small GTP-binding protein, rac, regulates growth factor-induced membrane ruffling / A.J. Ridley, H.F. Paterson, C.L. Johnston, D. Diekmann, A. Hall // Cell. 1992. — V. 70. — P. 401−410.
- Riggs, S.A. Jr. Blood flow and bone uptake of 99mTc-labeled methylene diphosphonate / S.A. Jr. Riggs, M.B. Wood, W.P. 3rd Cooney, P.J. Kelly // J. Orthop. Res. 1984. — V. 1. — No. 3. — P. 236−243.
- Ritter, M.A. High-LET radiations induce a large proportion of non-rejoining DNA breaks / M.A. Ritter, J.E. Cleaver, C.A. Tobias // Nature. -1977.-V. 266.-P, 653−655.
- Roelofs, A.J. Molecular mechanisms of action of bisphosphonates: current status / A.J. Roelofs, K. Thompson, S. Gordon, M.J. Rogers // Clin. Cancer Res. 2006. — V. 12 (20 Pt 2). — P. 6222.
- Rogers, M.J. New insights into the molecular mechanisms of action of bisphosphonates / M.J. Rogers // Curr. Pharm. Des. 2003. — V. 9. — No. 32.-P. 2643−2658.
- Ryan, P.J. Bone scintigraphy following intravenous pamidronate for Paget’s disease of bone / P.J. Ryan, T. Gibson, I. Fogelman // J. Nucl. Med. 1992. — V. 33. — P. 1589−1593.
- Sandler, E.D. Duration of etidronate effect demonstrated by serial bone scintigraphy / E.D. Sandler, M.T. Parisi, R.S. Hattner // J. Nucl. Med. -1991.-V. 32.-P. 1782−1784.
- Savio, E. Re-HEDP: pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose / E. Savio, J. Gaudiano, A.M. Robles, H. Baiter, A.
- Paolino, A. Lopez, J.C. Hermida, E. De Marco, G. Martinez, E. Osinaga, F.F. Knapp // BMC Nucl. Med. 2001. — V. 1. — No. 1. — P. 2.
- Schuemichen, C. Localization of 99mTc-diphosphonates in newly formed bone matrix as a measure of bone lesion detectability / C. Schuemichen, T. Krause, G. Umbach, T. Wolff//Nuklearmedizin. 1988. — V. 27. — No. 1. -P. 8−11.
- Sciuto, R. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients / R. Sciuto, A. Festa, R. Pasquaioni, A. Semprebene, S. Rea, S. Bergomi, C.L. Maini // Breast Cancer Res. Treat. 2001. — V. 66.-No. 2.-P. 101−109.
- Serafini, A.N. Radionuclide breast scanning in carcinoma of the breast / A.N. Serafini, M.M. Raskin, L.C. Zand, D.D. Watson // J. Nucl. Med. -1974.-V. 15.-No. 12.-P. 1149−1152.
- Shigematsu, M. New bone-seeking agent: animal study of Tc-99m-incadronate / M. Shigematsu, S. Shomi, H. Iwao, H. Ochi // Ann. Nucl. Med. 2002. — V. 16.-No. l.-P. 55−59.
- Shih, W.J. Bone agent localization in hepatic metastases / W.J. Shih, J.K. Han, S. Magoun, B. Wierzbinski // J. Nucl. Med. Technol. 1999. — V. 27. -No. l.-P. 38−40.
- Sinzinger, H. Background, reasons and benefits using the vienna protocol for the treatment of painful bone recurrences with 153Samarium-EDTMP / H. Sinzinger, K. Weiss, J. Hiltunen // Anticancer Res. 2009. — V. 29. -No. 5.-P. 3393−3395.
- Smith, F.W. Primary neuroblastoma uptake of 99mtechnetium methylene diphosphonate / F.W. Smith, D.L. Gilday, J.M. Ash, R.H. Reid // Radiology. 1980. — V. 137.-No. 2.-P. 501−504.
- Soderlund, V. Radiological diagnosis of skeletal metastases / V. Soderlund // Europ. Radiol. 1996. — V. 6. — P. 587−595.
- Steiner, R.M. Magnetic resonance imaging of diffuse bone marrow disease / R.M. Steiner, D.G. Mitchell, V.M. Rao, M.E. Schweitzer // Radiol. Clin. North Am. 1993. — V. 31. — No. 2. — P. 383−409.
- Storto, G. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases / G. Storto, M. Klain, G. Paone, R. Liuzzi, L. Molino, A. Marinelli, A. Soricelli, L. Pace, M. Salvatore // Bone. 2006. — V. 39.- No. 1.-P. 35−41.
- Stromqvist, B. Technetium-99m-methylenediphosphonate scintimetry after femoral neck fracture. A three-year follow-up study / B. Stromqvist, J. Brismar, L.I. Hansson, J. Palmer // Clin. Orthop. Relat. Res. 1984. — V. 182.-P. 177−189.
- Subramanian, G. New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate / G. Subramanian, J.G. McAfee, F.D. Thomas, T.A. Feld, C. Zapf-Longo, E. Palladino // Radiology. 1983. — V. 149. — No. 3. — P. 823−828.
- Tomblyn, M. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases / M. Tomblyn//Cancer Control.-2012.-V. 19.-No. 2.-P. 137−144.
- Traill, Z.C. Magnetic resonance imaging versus radionuclide scintigraphy in screening for bone metastases / Z.C. Traill, D. Talbot, S. Golding, F.V. Gleeson // Clin. Radiol. 1999. — V. 54. — No. 7. — P. 44851.
- Weininger, J. 186Re-HEDP: a potential therapeutic bone agent / J. Weininger, A.R. Ketring, E.A. Deutsch // Nuklearmedizin. 1984. — V. 23. -No. 2.-P. 81−82.
- Wilkinson, R.H. Jr. Concentration of Tc-99m methylenediphosphonate in hepatic metastases from squamous cell carcinoma / R.H. Jr. Wilkinson, J.T. Gaede//J. Nucl. Med. 1979.-V. 20.-No. 4.-P. 303−305.
- Xin, Z.F. Risedronate inhibits human osteosarcoma cell invasion / Z.F. Xin, Y.K. Kim, S.T. Jung // J. Exp. Clin. Cancer Res. 2009. — V. 28. — P. 105.
- Zhang, H. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients / H. Zhang, M. Tian, S. Li, J. Liu, S. Tanada, K. Endo // Cancer Biother. Radiopharm. 2003. — V. 18. — P. 719−726.